Table 2. Phase III trials with a BRAF inhibitor vs. chemotherapy and phase III trials with the combination of a BRAF inhibitor with a MEK inhibitor.

Agents	PR + CR (%)	PFS (months)	OS (months)	Interim OS rate (%)
BRIM III: vemurafenib vs. dacarbazine	48 vs. 5	5.3 vs. 1.6	13.2 vs. 9.6	6 months: 84 vs. 66; 12 months: 56 vs. 44
BREAK-3: dabrafenib vs. dacarbazine	50 vs. 7	5.1 vs. 2.7	18.2 vs. 15.6	5.1 months: 87.3 vs. 65; 10.6 months: 55 vs. 42
COMBO
COMBI-D: dabrafenib + trametinib vs. dabrafenib	67 vs. 51	9.3 vs. 8.8	NR	6 months: 93 vs. 85
COMBI-V: dabrafenib + trametinib vs. vemurafenib	64 vs. 51	11.4 vs. 7.3	NR vs. 12.7	12 months: 72 vs. 65
COBRIM: vemurafenib + cobimetinib vs. vemurafenib	68 vs. 45	9.9 vs. 6.2	NR	9 months: 81 vs. 73

PR, partial response; CR, complete response; PFS, progression free survival; OS, overall survival.